Comparison of Anti-VEGF Therapy and Corticosteroids in the Management of Uveitic Macular Edema
DOI:
https://doi.org/10.51985/Keywords:
Anti-VEGF, Bevacizumab, Central Macular Thickness, Corticosteroids, Uveitic macular edemaAbstract
Objective: To compare the anti-VEGF therapy and corticosteroids in improving best-corrected visual acuity (BCVA) and reducing central macular thickness (CMT) in UME patients.
Study design and Setting: A Prospective Cohort Study conducted at Sindh Institute of Ophthalmology and Vision Sciences, Hyderabad
Methodology: In this study 120 patients with UME were enrolled and 60 patients who received anti-VEGF Bevacizumab were placed Group A and those who were given Corticosteroids: intravitreal triamcinolone acetonide were placed in Group B. Primary outcomes were BCVA (logMAR), CMT and visual acuity improvement at 6 months. The secondary outcome was the total number of intravitreal injections administered per patient over 6 months, along with treatment-related adverse events.
Results: Both groups showed significant within-group improvement in BCVA and CMT, with a significant Group × Time interaction for BCVA and CMT (p<0.001). The corticosteroid group had significantly greater CMT reduction at 1 month and all subsequent measurements (between group p<0.001) and greater improvement in the number of lines of visual acuity at 6 months (between group p=0.019); however, the between-group difference in continuous BCVA at 6 months was not significant (p=0.099). IOP elevation (p=0.002) and cataract progression (p=0.001) were significantly more common with corticosteroids.
Conclusion: Intravitreal corticosteroid therapy was associated with greater anatomical improvement and a higher proportion of patients achieving clinically meaningful visual acuity gain compared with anti-VEGF therapy in uveitic macular edema, though this benefit came with a significantly higher risk of IOP elevation and cataract progression
Downloads
References
1. Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG.
Update in treatment of uveitic macular edema. Drug Des
Devel Ther. 2019 Feb 19;13:667-680. doi: 10.2147/DDDT.
S166092
2. Tallouzi MO, Moore DJ, Barry RJ, Calvert M, Mathers J,
Murray PI, et al. The effectiveness of pharmacological agents
for the treatment of uveitic macular edema (UMO): a systematic
review. Ocul Immunol Inflamm. 2019;27(4):658–80. doi:
10.1080/09273948.2019.1569243.
3. Teper SJ. Update on the Management of Uveitic Macular
Edema. J Clin Med. 2021 Sep 14;10(18):4133. doi: 10.3390/
jcm10184133.
4. Ayyildýz O, Durukan AH, Ozgurtas T, Gunal A. A comparison
of intravitreal bevacizumab and steroid activity in an
experimental uveitis model. Curr Eye Res. 2015 Dec;40(12):
1261-8. doi: 10.3109/02713683.2014.995310
5. Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM,
Vitale AT, et al. Periocular triamcinolone vs. intravitreal
triamcinolone vs. intravitreal dexamethasone implant for the
treatment of uveitic macular edema: the POINT trial.
Ophthalmology. 2019 Feb;126(2):283–95. doi: 10.1016/j.o
phtha.2018.08.021.
6. Acharya NR, Vitale AT, Sugar EA, Holbrook JT, Burke AE,
Thorne JE, et al. Intravitreal therapy for uveitic macular edema
ranibizumab versus methotrexate versus the dexamethasone
implant: the MERIT trial results. Ophthalmology. 2023
Sep;130(9):914–23. doi: 10.1016/j.ophtha.2023.04.011.
7. Patil NS, Mihalache A, Hatamnejad A, Popovic MM, Kertes
PJ, Muni RH. Intravitreal steroids compared with anti-VEGF
treatment for diabetic macular edema: a meta-analysis.
Ophthalmol Retina. 2023 Apr;7(4):289–99. doi: 10.1016/
j.oret.2022.10.008.
8. He Y, Ren XJ, Hu BJ, Lam WC, Li XR. A meta-analysis of
the effect of a dexamethasone intravitreal implant versus
intravitreal anti-vascular endothelial growth factor treatment
for diabetic macular edema. BMC Ophthalmol. 2018
May;18(1):121. doi: 10.1186/s12886-018-0779-1.
9. Sharma A, Bellala K, Dongre P, Reddy P. Anti-VEGF versus
dexamethasone implant (Ozurdex) for the management of
centre-involved diabetic macular edema (CiDME): a
randomized study. Int Ophthalmol. 2020 Jan;40(1):67–72.
doi: 10.1007/s10792-019-01151-3.
10. Qian T, Zhao M, Xu X. Comparison between anti-VEGF
therapy and corticosteroid or laser therapy for macular oedema
secondary to retinal vein occlusion: a meta-analysis. J Clin
Pharm Ther. 2017 Oct;42(5):519–29. doi: 10.1111/jcpt.12551.
11. Zhang W, Liu Y, Sang A. Efficacy and effectiveness of antiVEGF or steroids monotherapy versus combination treatment
for macular edema secondary to retinal vein occlusion: a
systematic review and meta-analysis. BMC Ophthalmol. 2022
Dec;22(1):472. doi: 10.1186/s12886-022-02682-7.
12. Lin Y, Ren X, Chen D. Steroid treatment in macular edema:
a bibliometric study and visualization analysis. Front
Pharmacol. 2022 Feb 22;13:824790. doi: 10.3389/fphar.
2022.824790.
13. Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt
RB, Rosenbaum JT, et al. Incidence of visual improvement
in uveitis cases with visual impairment caused by macular
edema. Ophthalmology. 2014 Feb;121(2):588–595.e1.
14. Invernizzi A, Pichi F, Symes R, Zagora S, Agarwal AK,
Nguyen P, et al. Twenty-four-month outcomes of inflammatory
choroidal neovascularisation treated with intravitreal antivascular endothelial growth factors: a comparison between
two treatment regimens. Br J Ophthalmol. 2020 Aug;104(8):
1052–6. doi: 10.1136/bjophthalmol-2019-315257.
15. Cheng ZA, Liu X. Comparing the efficacy of glucocorticoids
and anti-VEGF in treating diabetic macular edema: systematic
review and comprehensive analysis. Front Endocrinol. 2024
Mar 22;15:1342530. doi: 10.3389/fendo.2024.1342530.
16. Koc H, Alpay A, Ugurbas SH. Comparison of the efficacy of
intravitreal anti-VEGF versus intravitreal dexamethasone
implant in treatment resistant diabetic macular edema. BMC
Ophthalmol. 2023 Mar 13;23(1):97. doi: 10.1186/s12886-
023-02831-6.
17. Kelkar A, Kelkar J, Dutta S, Bolisetty M, Jain H, Labhsetwar
N. Management of coexisting cataract and diabetic macular
edema: a comparative study of dexamethasone implant versus
anti-VEGF agents injections. Int J Ophthalmol. 2026
Jan;19(1):56-62. doi: 10.18240/ijo.2026.01.07.
18. Zabaneh ID, Dunn T, Dunn K, Williams P. Comparative
incidence of endophthalmitis after intravitreal dexamethasone
implant versus anti-VEGF injections: a retrospective study.
Int J Retina Vitreous. 2026 Feb 23;12(1):50. doi: 10.1186
/s40942-026-00824-3.
19. Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW.
A 12-month, single-masked, randomized controlled study of
eyes with persistent diabetic macular edema after multiple
anti-VEGF injections to assess the efficacy of the
dexamethasone-delayed delivery system as an adjunct to
bevacizumab compared with continued bevacizumab
monotherapy. Retina. 2015 Aug;35(8):1604–14. doi: 10.1097/
IAE.0000000000000533.
20. Lee JY, Lee SY, Kim JY, Lee HJ, Jeong JH, Ma DJ. Effect
of alternate treatment with intravitreal anti-vascular endothelial
growth factor and steroid for treatment-naive diabetic macular
edema in a real-life setting. J Ocul Pharmacol Ther. 2020
Sep;36(7):555–62. doi: 10.1089/jop.2020.0012.
21. Cai X, Zhao J, Dang Y. Combination therapy with anti-VEGF
and intravitreal dexamethasone implant for macular edema
secondary to retinal vein occlusion. Curr Eye Res. 2024
Aug;49(8):872–8. doi: 10.1080/02713683.2024.2343055.
22. Bae YH, Kim SM, Kim JY, Bae SH, Kim H, Ma DJ. Effect
of alternate treatment with intravitreal corticosteroid and antiVEGF for macular edema secondary to retinal vein occlusion.
J Ophthalmol. 2021;2021:5948113. doi: 10.1155/2021/
5948113.
23. Cui BH, Zhou W, Wang WW, Yang H, Dong YL, Liu YY, et
al. Clinical efficacy of intravitreal corticoid as an adjunctive
therapy to anti-VEGF treatment of neovascular age-related
macular degeneration: a meta-analysis. Int J Ophthalmol.
2021 Jul 18;14(7):1092-9. doi: 10.18240/ijo.2021.07.19.
24. Kaya C, Zandi S, Pfister IB, Gerhardt C, Garweg JG. Adding
a corticosteroid or switching to another anti-VEGF in
insufficiently responsive wet age-related macular degeneration.
Clin Ophthalmol. 2019 Dec;13:2403–9. doi: 10.2147/
OPTH.S224456.
25. Kumar A, Kumar A, Kumar J, Bai G, Jeewnani R, Dembra
M, et al. Comparative efficacy of anti-vascular endothelial
growth factor (anti-VEGF) agents and corticosteroids in
managing diabetic retinopathy-associated diabetic macular
edema: a meta-analysis and comprehensive systematic review.
Cureus. 2024 Jan 8;16(1) :e51910. doi: 10.7759/cureus.51910.
26. Naz U, Naz S, Rizvi F, Kamil Z. Pattern of uveitis in a tertiary
care eye hospital setting in Pakistan: a comprehensive analysis.
Ocul Immunol Inflamm. 2025 Sep;33(7):1108–1112. doi:
10.1080/09273948.2024.2439903.
27. Putera I, Thiadens AAHJ, Larasmanah ASN, La Distia Nora
R, Dik WA, van Hagen PM, Rombach SM, Ten Berge JCEM.
Uveitic macular oedema in ocular tuberculosis patients in a
non-endemic country: characteristics, management, and visual
outcomes. Eye (Lond). 2025 Feb;39(3):593–601. doi:
10.1038/s41433-024-03577-1.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
